Safety and tolerability of odanacatib therapy in postmenopausal women with osteoporosis: results from the phase III long-term odanacatib fracture trial

@inproceedings{Papapoulos2014SafetyAT,
  title={Safety and tolerability of odanacatib therapy in postmenopausal women with osteoporosis: results from the phase III long-term odanacatib fracture trial},
  author={Socrates E Papapoulos and Mcclung and Bente Lomholt Langdahl and Kenneth G. Saag and Silvano Adami and H G Bone and T. J. de Villiers and Douglas P Kiel and Annie W C Kung and Praveen Kumar and Sk Lim and Xiaodong Ling and K Lippuner and Carlos A. Mautalen and Toshitaka Nakamura and Jacques Reginster and Ian R. Reid and Jose A. Rodriguez-Portales and Clémence Roux and Jan Walliser and Nelson B. Watts and Jos{\'e} Rub{\'e}n Zanchetta and Cristiano A. F. Zerbini and A. Rybak-Feiglin and Daniel Cohn and Carolyn Dasilva and C{\'e}line Le Bailly de Tilleghem and Arthur C. Santora and Boyd B. Scott and Nadia Verbruggen and Albert Leung and Alfonsa Anna Lombardi and Deborah M. Gurner},
  year={2014}
}

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-3 OF 3 CITATIONS

Odanacatib for the treatment of osteoporosis.

  • Expert opinion on pharmacotherapy
  • 2015
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Bone Biomechanics and Bone Quality: Effects of Pharmaceutical Agents Used to Treat Osteoporosis

  • Clinical Reviews in Bone and Mineral Metabolism
  • 2016
VIEW 1 EXCERPT
CITES BACKGROUND

Novel therapies for osteoporosis.

  • Metabolism: clinical and experimental
  • 2015
VIEW 1 EXCERPT
CITES BACKGROUND